In Brief: EDAP Technomed Group
This article was originally published in The Gray Sheet
Executive Summary
EDAP Technomed Group: Receives approvable letter from FDA for its premarket approval application for the Prostatron microthermy system, which is intended to treat benign prostatic hyperplasia. In October, FDA's Gastroenterology and Urology Devices Panel deemed the PMA approvable, based on the fulfillment of certain conditions ("The Gray Sheet" Oct. 23, p. 6). The agency sent the approvable letter during the week of Nov. 20, FDAers say...
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.